We are very excited to share that
the highly-anticipated Phase II results of our FDA-approved stem cell
treatment study have been released.
Building off the groundbreaking findings in Phase I, this is the
first study to show a broad array of regenerative improvements, and have very
exciting implications for patients moving forward. While further study of
these results is needed, notable findings include:
Significant improvement in walking speeds among patients who
require walking assistance
Improved bladder function, with 69% of
patients showing improved post-void residual volume
A positive increase in gray matter volume for patients with
less advanced disease progression, indicating the treatments could
potentially restore neuronal cells and reverse cognitive decline in
these patients
Notable biomarker changes, including a
decrease in the protein CCL2 (which is associated with inflammatory
diseases like MS) and an increase in the protein MMP9 (which indicates
an increase in microglial cells that repair the progression of MS)
Dr. Sadiq shared these results at the American Academy of
Neurology annual meeting in Boston last month, and we’ll be sure to share
further updates as we prepare the paper manuscript for publication.
We also
look forward to sharing more with you all on the path forward for this
research, including potentially investigating the impacts of increasing the
dosage of stem cell treatments. We’ll be sure to keep everyone posted on
logistics and how we’ll be coordinating the next steps for the study.
Please feel
free to share this news with your network – and as always, we’re deeply
appreciative of your support of the Center!
